Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 4/2024

Open Access 20-03-2024 | Semaglutide | Original Research Article

Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

Authors: Xi Tan, Victoria Divino, James Amamoo, Lin Xie, Katharine B. Coyle, Cory L. Gamble, Mico Guevarra, Yurek Paprocki, Aaron A. King

Published in: Clinical Drug Investigation | Issue 4/2024

Login to get access

Abstract

Background

The efficacy of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1RAs) has been established in several trials in people with type 2 diabetes mellitus (T2DM); however, real-world evidence on their effectiveness is limited. This study evaluated the effectiveness of OW GLP-1RA regarding glycemic and weight outcomes, and relative to DPP-4i in a comparator analysis.

Methods

This observational cohort study evaluated glycated hemoglobin (HbA1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide). Comparator analysis for the same outcome was performed for OW GLP-1RAs versus DPP-4i and semaglutide subgroup versus DPP-4i. A linked patient population from the IQVIA PharMetrics® Plus database and the Ambulatory Electronic Medical Records (AEMR) database was analyzed using data from January 2017 to April 2022. HbA1c and weight were assessed at baseline and at the end of the 12-month post-index period. Inverse probability of treatment weighting (IPTW) was used to adjust for imbalances in baseline patient characteristics in the comparator analysis.

Results

In the pre-post analysis, a greater numerical reduction in HbA1c and weight was observed for the semaglutide subgroup (N = 354) relative to the OW GLP-1RA cohort (N = 921). In the semaglutide subgroup, 52.5% and 34.2% of patients achieved HbA1c of < 7.0% and ≥ 5% weight loss, respectively. For the comparator analysis, the OW GLP-1RAs (N = 651) were significantly more effective (p < 0.001) in reducing HbA1c (− 1.5% vs. −  1.0%) and weight (− 3.2 kg vs. −  1.0 kg) than the DPP-4is (N = 431). Similarly, the semaglutide cohort (N = 251) also displayed more effectiveness (p < 0.001) in reducing HbA1c (− 1.7% vs. −  0.9%) and weight (− 4.1 kg vs. −  1.3 kg) than the respective DPP-4i cohort (N = 417). Patients initiating OW GLP-1RAs, including the semaglutide cohort, were at least twice as likely to achieve HbA1c and weight outcomes as well as composite outcomes compared with those initiating DPP-4is.

Conclusion

The study reinforces that OW GLP-1RAs are more effective in glycemic control and weight reduction compared with DPP-4is in people with T2DM in the real-world setting. These findings align with the recommendation in the current guidelines for utilizing glucose-lowering treatment regimens that support weight-management goals in people with T2DM.
Appendix
Available only for authorised users
Literature
1.
Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020;132(sup2):3–14.CrossRefPubMed
2.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-S57.
3.
Grewal S, Zaman N, Borgatta L, Nudy M, Foy AJ, Peterson B. Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus. Am J Cardiol. 2021;154:48–53.CrossRefPubMed
4.
Hupfeld C, Mudaliar S. Navigating the “MACE” in cardiovascular outcomes trials and decoding the relevance of atherosclerotic cardiovascular disease benefits versus heart failure benefits. Diabetes Obes Metab. 2019;21(8):1780–9.CrossRefPubMed
5.
Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne). 2021;12: 645507.CrossRefPubMedPubMedCentral
6.
7.
8.
9.
10.
11.
Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–10.CrossRefPubMed
12.
Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255–61.CrossRefPubMedPubMedCentral
13.
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–67.CrossRefPubMed
14.
Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US Clinical Practice (STAY Study). Diabetes Ther. 2022;13(1):175–87.CrossRefPubMed
15.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–66.CrossRefPubMed
16.
Pratley RE, Aroda VR, Lingvay I, Ludemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86.CrossRefPubMed
17.
Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1–2 oral anti-diabetic drugs. Diabetes Ther. 2018;9(3):1149–67.CrossRefPubMedPubMedCentral
18.
Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab. 2011;13(11):982–9.CrossRefPubMedPubMedCentral
19.
Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne). 2020;11:178.CrossRefPubMedPubMedCentral
20.
Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Grade Study Research Group, et al. Glycemia reduction in type 2 diabetes—glycemic outcomes. N Engl J Med. 2022;387(12):1063–74.CrossRefPubMed
21.
22.
Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.CrossRefPubMed
23.
24.
Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273–7.CrossRefPubMed
25.
Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.CrossRefPubMedPubMedCentral
26.
Xu L, Yu SQ, Gao L, Huang Y, Wu SS, Yang J, et al. Effects of incretin-based therapies on weight-related indicators among patients with type 2 diabetes: a network meta-analysis. Biomed Environ Sci. 2020;33(1):37–47.PubMed
27.
Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jodar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1–7 trials. Diabetes Metab. 2019;45(5):409–18.CrossRefPubMed
28.
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776–90.CrossRefPubMed
29.
Minze MG, Klein MS, Jernigan MJ, Wise SL, Fruge K. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2013;33(6):627–38.CrossRefPubMed
30.
Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–9.CrossRefPubMed
31.
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149–58.CrossRefPubMedPubMedCentral
32.
Ahren B, Masmiquel L, Kumar H, Sargin M, Karsbol JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.CrossRefPubMed
33.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.CrossRefPubMedPubMedCentral
34.
Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.CrossRefPubMed
35.
Campos C, Unger J. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Postgrad Med. 2021;133(8):843–53.CrossRefPubMed
36.
Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH. Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective Observational EXPERT Study. Diabetes Ther. 2021;12(3):879–96.CrossRefPubMedPubMedCentral
37.
Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12): e214182.CrossRefPubMedPubMedCentral
38.
Bae JP, Kadziola ZA, Liu D, Chinthammit C, Boye KS, Mather KJ. An early assessment of the real-world treatment patterns of type 2 diabetes: a comparison to the 2018 ADA/EASD Consensus Report Recommendations. Diabetes Ther. 2022;13(8):1499–510.CrossRefPubMedPubMedCentral
39.
Nair R, Mody R, Yu M, Cowburn S, Konig M, Prewitt T. Real-world treatment patterns of glucose-lowering agents among patients with type 2 diabetes mellitus and cardiovascular disease or at risk for cardiovascular disease: an observational, cross-sectional retrospective study. Diabetes Ther. 2022;13(11–12):1921–32.CrossRefPubMed
40.
Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, et al. Prescription of glucagon-like peptide-1 receptor agonists by cardiologists. J Am Coll Cardiol. 2019;73(12):1596–8.CrossRefPubMedPubMedCentral
41.
Arnold SV, de Lemos JA, Zheng L, Rosenson RS, Ballantyne CM, Alam S, et al. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023;25(6):1750–7.CrossRefPubMed
42.
Romera I, Rubio-de Santos M, Artola S, Suarez Fernandez C, Conget I. GLP-1 RAs in Spain: a short narrative review of their use in real clinical practice. Adv Ther. 2023;40(4):1418–29.CrossRefPubMedPubMedCentral
Metadata
Title
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)
Authors
Xi Tan
Victoria Divino
James Amamoo
Lin Xie
Katharine B. Coyle
Cory L. Gamble
Mico Guevarra
Yurek Paprocki
Aaron A. King
Publication date
20-03-2024
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 4/2024
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-024-01354-2

Other articles of this Issue 4/2024

Clinical Drug Investigation 4/2024 Go to the issue

Research Letter

Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis

Review Article

Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far

Research Letter

Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study

Original Research Article

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

Original Research Article

Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan